This dataset is a directory of the different pharmaceutical companies in the United States and the European Union. It includes the company’s specialization, physical address, contact details, email and website links.

Comprehensive dataset containing 10 verified Pharmaceutical company businesses in ME with complete contact information, ratings, reviews, and location data.

This statistic shows the 2025 ranking of the top 10 biotech and pharmaceutical companies worldwide, based on net income. U.S.-based company Johnson & Johnson was ranked first with a net income of **** billion U.S. dollars. Biotech and pharmaceutical companiesJohnson & Johnson and Merck & Co., both based in the United States, are among the world’s largest biotechnology and pharmaceutical companies based on their net incomes of approximately **** billion U.S. dollars and **** billion U.S. dollars, respectively, as of 2025. Johnson & Johnson generated some **** billion U.S. dollars of revenue in 2024. Pfizer had record-high annual revenues during the COVID-19 vaccination campaign, exceeding 100 billion U.S. dollars in 2022.

Story of a former blockbuster Lyrica was once one of Pfizer’s most successful products. It is an anticonvulsant for neuropathic pain and is also used as therapy for partial seizures. In the EU and in Russia, Lyrica has also been approved to treat general anxiety disorder. In 2017, this prescription medication generated some **** billion U.S. dollars in revenue.

Comprehensive dataset containing 93 verified Pharmaceutical company businesses in Georgia with complete contact information, ratings, reviews, and location data.

Db Pharmaceutical Company Export Import Data. Follow the Eximpedia platform for HS code, importer-exporter records, and customs shipment details.

This statistic shows the ranking of the global top 10 biotech and pharmaceutical companies worldwide, based on revenue. The values are based on a 2025 database. U.S. pharmaceutical company Pfizer was ranked first, with a total revenue of around ** billion U.S. dollars. Biotech and pharmaceutical companiesPharmaceutical companies are best known for manufacturing pharmaceutical drugs. These drugs have the aim to diagnose, to cure, to treat, or to prevent diseases. The pharmaceutical sector represents a huge industry, with the global pharmaceutical market being worth around *** trillion U.S. dollars. The best known top global pharmaceutical players are Pfizer, Merck, and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Most of these companies are involved not only in pure pharmaceutical business, but also manufacture medical technology and consumer health products, vaccines, etc. There are both pure play biotechnology companies and pharmaceutical companies which among other products also produce biotech products within their biotechnological divisions. Most of the leading global pharmaceutical companies have biopharmaceutical divisions. Although not a pure play biotech firm, Roche from Switzerland is among the companies with the largest revenues from biotechnology products worldwide. In contrast, California-based company Amgen was one of the world’s first large pure play biotech companies. Biotech companies use biotechnology to generate their products, most often medical drugs or agricultural genetic engineering. The latter segment is dominated by companies like Bayer CropScience and Syngenta. The United Nations Convention on Biological Diversity defines biotechnology as follows: "Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use." In fact, biotechnology is thousands of years old, used in agriculture, food manufacturing and medicine.

Based on revenues latest available as of 2025, Johnson & Johnson was the top ranked pharmaceutical company in the United States. Johnson & Johnson generated around ** billion U.S. dollars worldwide, which is around ** billion U.S. dollars more than the next ranked U.S. pharmaceutical company, Pfizer. However, Johnson & Johnson's total revenue includes also sales from their medical device division, while Pfizer is a pure-play biopharmaceutical company. Branded and generic drugs: What are the differences? Patented products marketed by pharmaceutical companies are referred to as branded. The protection of the patent means that the company, which has spent a large amount of money researching and developing the product, can exclusively sell the drug – often at a high price to recoup its investment. Once the patent expires, other companies may produce generic versions of the product, which contain the same key ingredients.

🧪 Discover the Power of a Verified Pharma Database in IndiaIn a fast-evolving healthcare ecosystem, pharmaceutical businesses, distributors, medical marketers, and health-tech startups need access to real-time, accurate, and structured pharma data to make informed decisions and scale their operations.…

IntroductionInteractions between pharmaceutical companies and healthcare providers are increasingly scrutinized by academics, professionals, media, and politicians. Most empirical studies and professional guidelines focus on unilateral donor-recipient types of interaction and overlook, or fail to distinguish between, more reciprocal types of interaction. However, the degree of goal alignment and potential for value creation differs in these two types of interactions. Failing to differentiate between these two forms of interaction between pharmaceutical companies and healthcare providers could thus lead to biased conclusions regarding their desirability. This study reviews the empirical literature regarding the effects of bilateral forms of interactions between pharmaceutical companies and healthcare providers in order to explore their effects.Material and methodsWe searched two medical databases (i.e. PubMed and Cochrane Library) and one business database (i.e. EBSCO) for empirical, peer-reviewed articles concerning any type of bilateral interaction between pharmaceutical companies and healthcare providers. We included quantitative articles which were written in English and published between January 1st, 2000 and October 31st, 2016, and where the title or abstract included a combination of synonyms of the following keywords: pharmaceutical companies, healthcare providers, interaction, and effects.ResultsOur search results yielded 10 studies which were included in our analysis. These studies focused on either research-oriented interaction or on education-oriented interaction. The included studies reported various outcomes of interaction such as prescribing behavior, ethical dilemmas, and research output. Regardless of the type of interaction, the studies either reported no significant effects or ambivalent outcomes such as affected clinical practice or ethical issues.Discussion and conclusionThe effects of bilateral interactions reported in the literature are similar to those reported in studies concerning unilateral interactions. The theoretical notion that bilateral interactions between pharmaceutical companies and healthcare providers have different effects given their increased level of goal alignment thus does not seem to hold. However, most of the empirical studies focus on intermediary, provider-level, outcomes such as altered prescribing behavior. Outcomes at the health system level such as overall costs and quality of care are overlooked. Further research is necessary in order to disentangle various forms of value created by different types of interactions between pharmaceutical companies and healthcare providers.

Comprehensive dataset containing 138 verified Pharmaceutical company businesses in Finland with complete contact information, ratings, reviews, and location data.

Comprehensive dataset containing 98 verified Pharmaceutical company businesses in Norway with complete contact information, ratings, reviews, and location data.

About the Dataset: Pharmaceutical Products Pricing and Availability Data in Pakistan

This dataset contains information about pharmaceutical product pricing and availability in Pakistan. The data was collected from various sources and compiled into a structured format for analysis. The dataset consists of 1630 entries with 7 columns, including:

Name: The name of the pharmaceutical product. Company: The company manufacturing or distributing the product. Price_before: The product's price before any discount is applied. Discount: The discount offered on the product, if applicable. Price_After: The price of the product after applying any discount. Pack_Size: The size or quantity of the product's packaging. Availability: The availability status of the product.

The dataset provides insights into the pricing trends and availability of pharmaceutical products in Pakistan, which can be valuable for various stakeholders including consumers, healthcare professionals, and policymakers. It can be used for analysis, research, and decision-making in the pharmaceutical industry.

Data Overview: Entries: 1630 Missing Values: Some columns have missing values, such as 'Name', 'Company', 'Price_before', 'Discount', 'Price_After', 'Pack_Size', and 'Availability'. Data Types: The dataset consists of object types for textual data and one float type for numerical data.

Potential Uses: This dataset can be used for a variety of purposes, including:

• Analyzing pricing trends and patterns of different drugs in Pakistan.
• Studying the affordability and accessibility of essential medicines in Pakistan.
• Tracking the performance of different pharmaceutical companies in the Pakistani market.
• Identifying potential areas for improving access to affordable medicines in Pakistan.

Limitations: It is important to note that this dataset only includes data on the maximum retail prices of pharmaceutical products. The actual price consumers pay may vary depending on the pharmacy and other factors. Additionally, the dataset does not include information on the quality of the pharmaceutical products.

I hope this description is helpful!

Comprehensive dataset containing 47 verified Pharmaceutical company businesses in XK with complete contact information, ratings, reviews, and location data.

BackgroundPharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates that promotion may adversely influence prescribing, physicians hold a wide range of views about pharmaceutical promotion. The objective of this review is to examine the relationship between exposure to information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing.Methods and FindingsWe searched for studies of physicians with prescribing rights who were exposed to information from pharmaceutical companies (promotional or otherwise). Exposures included pharmaceutical sales representative visits, journal advertisements, attendance at pharmaceutical sponsored meetings, mailed information, prescribing software, and participation in sponsored clinical trials. The outcomes measured were quality, quantity, and cost of physicians' prescribing. We searched Medline (1966 to February 2008), International Pharmaceutical Abstracts (1970 to February 2008), Embase (1997 to February 2008), Current Contents (2001 to 2008), and Central (The Cochrane Library Issue 3, 2007) using the search terms developed with an expert librarian. Additionally, we reviewed reference lists and contacted experts and pharmaceutical companies for information. Randomized and observational studies evaluating information from pharmaceutical companies and measures of physicians' prescribing were independently appraised for methodological quality by two authors. Studies were excluded where insufficient study information precluded appraisal. The full text of 255 articles was retrieved from electronic databases (7,185 studies) and other sources (138 studies). Articles were then excluded because they did not fulfil inclusion criteria (179) or quality appraisal criteria (18), leaving 58 included studies with 87 distinct analyses. Data were extracted independently by two authors and a narrative synthesis performed following the MOOSE guidelines. Of the set of studies examining prescribing quality outcomes, five found associations between exposure to pharmaceutical company information and lower quality prescribing, four did not detect an association, and one found associations with lower and higher quality prescribing. 38 included studies found associations between exposure and higher frequency of prescribing and 13 did not detect an association. Five included studies found evidence for association with higher costs, four found no association, and one found an association with lower costs. The narrative synthesis finding of variable results was supported by a meta-analysis of studies of prescribing frequency that found significant heterogeneity. The observational nature of most included studies is the main limitation of this review.ConclusionsWith rare exceptions, studies of exposure to information provided directly by pharmaceutical companies have found associations with higher prescribing frequency, higher costs, or lower prescribing quality or have not found significant associations. We did not find evidence of net improvements in prescribing, but the available literature does not exclude the possibility that prescribing may sometimes be improved. Still, we recommend that practitioners follow the precautionary principle and thus avoid exposure to information from pharmaceutical companies.Please see later in the article for the Editors' Summary

This dataset contains the Marketing Status part to build the Drugs@FDA database. Drugs at FDA is a database that provides information of drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

This dataset contains the Applications part to build the Drugs@FDA database. Drugs at FDA is a database of FDA Approved Drug Products available on the FDA official website. It provides information of drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

Comprehensive dataset containing 127 verified Pharmaceutical company businesses in Ohio, United States with complete contact information, ratings, reviews, and location data.

Drug Manufacturer Contact Information contains Optional Effective Date, Termination Date (if applicable), and Legal, Invoice and Technical Contact information for each drug company participating in the Medicaid Drug Rebate Program. For more information see: https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html

China Pharmaceutical: YoY: Net Fixed Asset data was reported at 8.040 % in Nov 2007. This records a decrease from the previous number of 8.830 % for Aug 2007. China Pharmaceutical: YoY: Net Fixed Asset data is updated monthly, averaging 16.000 % from Jan 2003 (Median) to Nov 2007, with 53 observations. The data reached an all-time high of 20.460 % in Mar 2003 and a record low of 8.040 % in Nov 2007. China Pharmaceutical: YoY: Net Fixed Asset data remains active status in CEIC and is reported by National Bureau of Statistics & YYTJ. The data is categorized under China Premium Database’s Pharmaceutical Sector – Table CN.RTC: Pharmaceutical Industry.